Form 4: Puma Biotechnology Director Sells Over 11,000 Shares Under Pre-Arranged Trading Plan

Allison Dorval, a Director at Puma Biotechnology, Inc., sold 11,610 shares of common stock for approximately $3.4 per share on June 13, 2025, as part of a pre-scheduled Rule 10b5-1 trading plan.

Summary

• Allison Dorval, a Director of Puma Biotechnology, Inc. (PBYI), executed a sale of common stock.
• The transaction involved the disposition of 11,610 shares of PBYI common stock.
• The shares were sold on June 13, 2025, at a weighted average price of $3.4 per share.
• The sale price ranged from $3.34 to $3.48 per share.
• The transaction was conducted pursuant to a Rule 10b5-1(c) trading plan, which was adopted on March 12, 2025.
• Following this transaction, Allison Dorval directly beneficially owns 75,390 shares of Puma Biotechnology, Inc. common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the fact that it was conducted under a pre-arranged Rule 10b5-1 plan mitigates concerns about opportunistic trading, making it a routine and expected disclosure.

Positives

• The sale was conducted under a Rule 10b5-1(c) trading plan, indicating it was pre-scheduled and not based on immediate, non-public information, which enhances transparency and reduces concerns about opportunistic insider trading.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived by investors as a lack of confidence in the company's future prospects, especially if it represents a significant portion of the insider's holdings.

Future Outlook

The document, being a Form 4, does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. It is a routine disclosure of a director's stock activity.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a signal, though the 10b5-1 plan suggests it's for personal financial planning rather than a reflection of company performance.

Key Dates

Keywords

Puma Biotechnology, PBYI, SEC Form 4, Insider Sale, Stock Transaction, Director Stock Sale, Rule 10b5-1 Plan, Equity Disposition